KIF20A and cancer: Subsequent work led to the discovery that 3 different HLA-A2-restricted MKLP2-derived peptides could activate human cytotoxic CD8+ T cells and that such T cells could effectively kill HLA-A2+ MKLP2-expressing cancer cells in vitro [98].